These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 37965350

  • 1. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
    Daetwyler E, Zippelius A, Danioth S, Donath MY, Gut L.
    Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
    [Abstract] [Full Text] [Related]

  • 2. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ikeda T, Ishihara H, Nemoto Y, Tachibana H, Fukuda H, Yoshida K, Takagi T, Iizuka J, Hashimoto Y, Ishida H, Kondo T, Tanabe K.
    Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
    Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K.
    Int J Urol; 2023 Oct; 30(10):866-874. PubMed ID: 37278575
    [Abstract] [Full Text] [Related]

  • 14. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
    Zhang HC, Luo W, Wang Y.
    J Immunother Cancer; 2019 Feb 18; 7(1):47. PubMed ID: 30777137
    [Abstract] [Full Text] [Related]

  • 15. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 16. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr 02; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 17. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C, Maeng H, Brofferio A, Apolo AB, Sathya B, Arai AE, Gulley JL, Bilusic M.
    J Immunother Cancer; 2018 Dec 18; 6(1):150. PubMed ID: 30563577
    [Abstract] [Full Text] [Related]

  • 18. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.
    Urol Oncol; 2019 Jun 18; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I, Malinzak M, Salama AKS.
    J Immunother Cancer; 2018 Jul 31; 6(1):77. PubMed ID: 30064495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.